Ingredient Safety

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act (S. 2994), introduced into the U.S. Senate by Senators Bob Casey Jr. (D-PA) and Lisa Murkowski (R-AK).

CHPA applauds the state of Georgia for becoming the thirty-third state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx).

CHPA, which represents leading manufacturers of OTC cough medicines, strongly supports this legislation and is joined many by substance abuse prevention organizations such as the Community Anti-Drug Coalitions of America and the Partnership for Drug-Free Kids.

CHPA released the following statement today in support of a Florida law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

CHPA commends the U.S. House of Representatives for swift passage of the Microbead-Free Waters Act of 2015 (H.R. 1321).

CHPA expresses its gratitude to New Jersey's governor, senator, and assembly members for shepherding the bill through the legislature. CHPA has long supported state efforts to curb teen OTC cough medicine abuse.

CHPA released the following statement in response to an article in Pediatrics, the official journal of the American Academy of Pediatrics, which reported a decline in emergency department visits for unsupervised medication exposures in young children.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).